AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31058633 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex and increasing age
Number of subjects: 60
Study 28288075 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-embedded best practice alert (BPA) for HCV testing
Number of subjects: 25620
Study 28288075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BPA)
Number of subjects: 25620
Study 25885106 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg QD sc
Number of subjects: 32
Study 25885106 — intervention group
Group type: COMPARATOR
Intervention: metformin 1000 mg BID po
Number of subjects: 32
Study 23612494 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Botulinum Toxin‐A (75IU Dysport®)
Number of subjects: 50
Study 23612494 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine (10mg/day)
Number of subjects: 50
Study 21197615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (20 mg p.o.)
Number of subjects: 43
Study 21197615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18580064 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating heart technique (n = 22)
Number of subjects: 45
Study 18580064 — intervention group
Group type: COMPARATOR
Intervention: Cardioplegic cardiac arrest technique (n = 23)
Number of subjects: 45
Study 17531691 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 5011
Study 17531691 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 5011
Study 17531691 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia (extended study period)
Number of subjects: 5011
Study 17531691 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (extended study period)
Number of subjects: 5011
Study 15364759 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy (during application)
Number of subjects: 32
Study 15364759 — intervention group
Group type: COMPARATOR
Intervention: nCPAP therapy (before application)
Number of subjects: 32
Study 15364759 — intervention group
Group type: EXPERIMENTAL
Intervention: Wakefulness
Number of subjects: 32
Study 15364759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 32
Study 11589843 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine 5 mg
Number of subjects: 162
Study 11589843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 9647968 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens plus methyltestosterone for four and eight weeks of daily drug administration
Number of subjects: 0
Study 9647968 — intervention group
Group type: COMPARATOR
Intervention: Esterified estrogens alone for four and eight weeks of daily drug administration
Number of subjects: 0
Study 7991990 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein expression in early stomach cancers
Number of subjects: 309
Study 7991990 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein expression in advanced stomach cancers
Number of subjects: 309
Study 7991990 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein expression in recurrent or inoperable metastatic stomach cancers
Number of subjects: 309
Study 7991990 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein levels in serum of patients with primary stomach cancers
Number of subjects: 309
Study 7991990 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein levels in serum of patients with recurrent or inoperable metastatic stomach cancers
Number of subjects: 309
Study 7991990 — intervention group
Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein levels during chemotherapy in recurrent or inoperable metastatic disease
Number of subjects: 309
Study 2647667 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (stepwise relaxation/hypnosis/autogenic training/cognitive behavior therapy)
Number of subjects: 1015
Study 2647667 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (thermal/photoplethysmograph/EMG)
Number of subjects: 1015
Study 2647667 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-electrical therapy (TENS/Neurotransmitter Modulation)
Number of subjects: 1015
Study 2647667 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment (combination of any of the above two treatments)
Number of subjects: 1015
Study 2647667 — intervention group
Group type: EXPERIMENTAL
Intervention: Short term intervention (15 or less treatments)
Number of subjects: 1015
Study 2647667 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term intervention (greater than 15 treatments)
Number of subjects: 1015
Study 31955968 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine combined with 0.3 μg/mL sufentanil
Number of subjects: 60
Study 31955968 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil combined with 0.1% ropivacaine
Number of subjects: 60
Study 31955968 — intervention group
Group type: EXPERIMENTAL
Intervention: Labor analgesia
Number of subjects: 60
Study 31955968 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 60
Study 31745043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash containing essential oils and curcumin (MEC) as an adjunct to scaling and root planing (SRP)
Number of subjects: 45
Study 31745043 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash as an adjunct to scaling and root planing (SRP)
Number of subjects: 45
Study 31745043 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 45
Study 28289044 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendship-based network-targeting algorithm with established care interventions
Number of subjects: 30000
Study 28289044 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalable methods of network targeting
Number of subjects: 30000
Study 24668575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% isobaric levobupivacaine with 25 mcg fentanyl
Number of subjects: 100
Study 23869899 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners in Dementia Care (PDC) program
Number of subjects: 486
Study 20965956 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransfusion of pericardial blood
Number of subjects: 13
Study 20965956 — intervention group
Group type: COMPARATOR
Intervention: Discarding pericardial blood
Number of subjects: 13
Study 18325150 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to Community Mental Health Teams (CMHTs)
Number of subjects: 0
Study 18325150 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct doctor-to-doctor communication strategies
Number of subjects: 0
Study 18325150 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of intermediate or 'Tier 2' services
Number of subjects: 0
Study 17129547 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg daily for 4 weeks, followed by 2 weeks without treatment, and lamivudine 150 mg daily for 4 weeks; followed by lamivudine plus interferon alfa 2b (10 MIU every other day) for 24 weeks and continuous lamivudine 150 mg daily to complete 58 weeks
Number of subjects: 44
Study 17129547 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine 150 mg daily for 4 weeks plus interferon alfa 2b (10 MIU every other day) for 24 weeks, without prednisone
Number of subjects: 44
Study 15361771 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fish meal
Number of subjects: 69
Study 15361771 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-reduction regimen
Number of subjects: 69
Study 15361771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fish meal and weight loss
Number of subjects: 69
Study 15361771 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 11328261 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically-derived porcine secretin
Number of subjects: 6
Study 11328261 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic porcine secretin
Number of subjects: 6
Study 11328261 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human secretin
Number of subjects: 6
Study 9309708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (36‐38 mg/kg/day)
Number of subjects: 13
Study 9309708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8358976 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 33
Study 8358976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3739805 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium drinkers consuming an experimental dose similar to their usual dose
Number of subjects: 60
Study 3739805 — intervention group
Group type: EXPERIMENTAL
Intervention: Light drinkers
Number of subjects: 60
Study 3739805 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers consuming a dose lower than their usual dose
Number of subjects: 60
Study 28971273 — intervention group
Group type: EXPERIMENTAL
Intervention: GTO training, tools, and technical assistance
Number of subjects: 32
Study 28971273 — intervention group
Group type: COMPARATOR
Intervention: Making Proud Choices (MPC) without GTO
Number of subjects: 32
Study 26932401 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 280
Study 26932401 — intervention group
Group type: COMPARATOR
Intervention: MOAA/S monitoring
Number of subjects: 280
Study 24559846 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD + stearate (9g/d of encapsulated stearate)
Number of subjects: 100
Study 24559846 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD + linoleate (9g/d of encapsulated linoleate)
Number of subjects: 100
Study 24559846 — intervention group
Group type: COMPARATOR
Intervention: HFD + placebo
Number of subjects: 100
Study 22658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index (LAVI) > 32 ml/m(2)
Number of subjects: 130
Study 22658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 130
Study 22658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LVM) indexed to height(2.7)
Number of subjects: 130
Study 22658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural logarithm BNP
Number of subjects: 130
Study 22658300 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure levels, body mass index, age
Number of subjects: 130
Study 22658300 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameters of LV diastolic function
Number of subjects: 130
Study 20886787 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 80
Study 20886787 — intervention group
Group type: COMPARATOR
Intervention: Medication (Sodium Hyaluronate eye drops, 1 drop three times per day)
Number of subjects: 80
Study 18178395 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 253
Study 15807861 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-precipitated autoclaved Leishmania major (Alum/ALM) +/‐ bacille Calmette‐Guerin (BCG)
Number of subjects: 44
Study 14656785 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging (UG)
Number of subjects: 60
Study 14656785 — intervention group
Group type: COMPARATOR
Intervention: Conventional method using loss of resistance technique (CG)
Number of subjects: 60
Study 10721929 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate daily from Monday to Friday
Number of subjects: 312
Study 10721929 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate 2 d/wk and 3 d placebo (intermittent)
Number of subjects: 312
Study 10721929 — intervention group
Group type: COMPARATOR
Intervention: Placebo from Monday to Friday
Number of subjects: 312
Study 9188929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 micrograms once daily for 4 weeks)
Number of subjects: 114
Study 9188929 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (10 mg once daily for 4 weeks)
Number of subjects: 114
Study 1348000 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol (50 micrograms, 8.3 x 10(‐8) M)
Number of subjects: 10
Study 1348000 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (200 micrograms, 3.5 x 10(‐7) M)
Number of subjects: 10
Study 1348000 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 1348000 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 10
Study 1348000 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 10
Study 3549875 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg atropine
Number of subjects: 0
Study 3549875 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg glycopyrrolate
Number of subjects: 0
Study 3549875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30099126 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast computed tomographic urography
Number of subjects: 475
Study 30099126 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced computed tomographic urography
Number of subjects: 475
Study 26331692 — intervention group
Group type: EXPERIMENTAL
Intervention: GW406381 (COX-2 inhibitor)
Number of subjects: 400
Study 25352893 — intervention group
Group type: EXPERIMENTAL
Intervention: Funnel technique
Number of subjects: 14
Study 25352893 — intervention group
Group type: COMPARATOR
Intervention: Magerl technique
Number of subjects: 14
Study 23387245 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga Nidra practice (35-40 minutes/day, five days a week for six months)
Number of subjects: 150
Study 23387245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study 20457702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment
Number of subjects: 77
Study 20457702 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 77
Study 20457702 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment (no identified aetiology)
Number of subjects: 77
Study 20457702 — intervention group
Group type: COMPARATOR
Intervention: Vigabatrin (no identified aetiology)
Number of subjects: 77
Study 18971490 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insulin therapy (continuous infusion of insulin at a dose of 0.05 U/kg/hour with 20% dextrose support)
Number of subjects: 195
Study 18971490 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insulin therapy
Number of subjects: 195
Study 18971490 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard neonatal care)
Number of subjects: 195
Study 15897845 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral rofecoxib
Number of subjects: 49
Study 15897845 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 49
Study 15897845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 12634885 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study 12634885 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy (e.g. amiodarone)
Number of subjects: 0
Study 12634885 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy and angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 12634885 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0
Study 9684946 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) in rats
Number of subjects: 0
Study 9684946 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg hypericum extracts (14.8 mg hyperforin) in human volunteers
Number of subjects: 0
Study 9684946 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated dose of 3 x 300 mg/day of the extract in human volunteers
Number of subjects: 0
Study 9684946 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of 900 or 1200 mg of extract in human volunteers
Number of subjects: 0
Study 10155065 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 742
Study 2965126 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg teicoplanin given intravenously on induction of anaesthesia
Number of subjects: 146
Study 2965126 — intervention group
Group type: COMPARATOR
Intervention: Three perioperative injections of cefuroxime
Number of subjects: 146
Study 29212987 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quintiles of estimated CHD risk per prediction model
Number of subjects: 996
Study 29212987 — intervention group
Group type: EXPERIMENTAL
Intervention: All prediction models
Number of subjects: 996
Study 26970533 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR) - single dose rituximab every 3 months until treatment failure
Number of subjects: 131
Study 26970533 — intervention group
Group type: COMPARATOR
Intervention: Retreatment Rituximab (RR) - rituximab weekly for 4 weeks at the time of each progression until treatment failure
Number of subjects: 131
Study 26970533 — intervention group
Group type: COMPARATOR
Intervention: Retreatment Rituximab (RR)
Number of subjects: 131
Study 26970533 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 131
Study 26970533 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MR and RR
Number of subjects: 131
Study 23839225 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Needs Diversionary Program (SNDP)
Number of subjects: 328
Study 23839225 — intervention group
Group type: COMPARATOR
Intervention: Other court‐ordered programs
Number of subjects: 328
Study 23782594 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg canagliflozin
Number of subjects: 383
Study 23782594 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 383
Study 23782594 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg canagliflozin
Number of subjects: 383
Study 23782594 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin
Number of subjects: 383
Study 23782594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 21656474 — intervention group
Group type: EXPERIMENTAL
Intervention: AVF ligature (group A)
Number of subjects: 162
Study 21656474 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous endovenorrhaphy (group B)
Number of subjects: 162
Study 21656474 — intervention group
Group type: COMPARATOR
Intervention: Transvenous endovenorrhaphy (for recurrences)
Number of subjects: 162
Study 19468244 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos AO intraocular lens (IOL)
Number of subjects: 50
Study 19468244 — intervention group
Group type: COMPARATOR
Intervention: Akreos Adapt intraocular lens (IOL)
Number of subjects: 50
Study 19468244 — intervention group
Group type: EXPERIMENTAL
Intervention: Akreos AO IOL
Number of subjects: 50
Study 19468244 — intervention group
Group type: COMPARATOR
Intervention: Akreos Adapt IOL
Number of subjects: 50
Study 16828533 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol HCl administered before acquisition
Number of subjects: 28
Study 16828533 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol HCl administered following extinction trials
Number of subjects: 28
Study 16828533 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned stimuli were colored circles with a 'highly annoying' electrical stimulus as UCS
Number of subjects: 28
Study 16828533 — intervention group
Group type: COMPARATOR
Intervention: Non-threat condition
Number of subjects: 28
Study 16828533 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition
Number of subjects: 28
Study 15272106 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 52
Study 15272106 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (selective serotonin reuptake inhibitor antidepressant)
Number of subjects: 52
Study 11383378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (1, 2.5, 5, 10, 20, 40, and 80 mg/day)
Number of subjects: 0
Study 11383378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg)
Number of subjects: 317
Study 9241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Probucol + Multivitamins)
Number of subjects: 317
Study 9241125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (30,000 IU beta carotene, 500 mg vitamin C, 700 IU vitamin E)
Number of subjects: 317
Study 9241125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 317
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0
Study 8098339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8098339 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine bronchoprovocation
Number of subjects: 0
Study 2986562 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative percutaneous transhepatic drainage (PTD)
Number of subjects: 75
Study 2986562 — intervention group
Group type: COMPARATOR
Intervention: Surgery without preoperative drainage
Number of subjects: 75
Study 29956413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotypical images
Number of subjects: 240
Study 29956413 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral images
Number of subjects: 240
Study 29956413 — intervention group
Group type: EXPERIMENTAL
Intervention: Counter-stereotypical images
Number of subjects: 240
Study 29956413 — intervention group
Group type: EXPERIMENTAL
Intervention: No images
Number of subjects: 240